Latest & greatest articles for memantine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on memantine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on memantine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for memantine

41. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis

Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis Maidment ID, Fox CG, Boustani M, Rodriguez J, Brown RC, Katona CL CRD summary This review assessed efficacy of memantine on dementia-related behavioural (...) and psychological symptoms and concluded that treatment appeared to be beneficial. Although the authors offered an appropriately cautious conclusion based on the limited evidence presented, the reliability of the review is potentially compromised by bias and error in the search and selection of studies. Authors' objectives To assess the efficacy of memantine as a therapeutic agent for the treatment of behavioural and psychological symptoms related to dementia. Searching MEDLINE, EMBASE, PsycINFO, Cochrane

DARE.2008

42. Review: Cholinesterase inhibitors and memantine consistently but marginally improve symptoms of dementia

Review: Cholinesterase inhibitors and memantine consistently but marginally improve symptoms of dementia Review: Cholinesterase inhibitors and memantine consistently but marginally improve symptoms of dementia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: Cholinesterase inhibitors and memantine consistently but marginally improve symptoms of dementia Article Text Therapeutics Review: Cholinesterase inhibitors and memantine consistently but marginally improve symptoms of dementia Statistics from Altmetric.com No Altmetric data available

Evidence-Based Mental Health2008

43. Meta-analysis of six-month memantine trials in Alzheimer's disease

Meta-analysis of six-month memantine trials in Alzheimer's disease Meta-analysis of six-month memantine trials in Alzheimer's disease Meta-analysis of six-month memantine trials in Alzheimer's disease Smith Doody R, Tariot P N, Pfeiffer E, Olin J T, Graham S M CRD summary This review compared memantine with placebo in the treatment of probable Alzheimer's disease (AD). The authors concluded that memantine is effective and safe across the spectrum of disease severity. The authors' conclusions (...) reflect the findings of the review for patients with moderate to severe AD and appear reliable. However, benefits were not reported for all outcomes in patients with mild to moderate AD. Authors' objectives To assess the efficacy and safety of memantine in Alzheimer's disease (AD), and to determine the effects in differing severities of disease. Searching MEDLINE, BIOSIS Previews, International Pharmaceutical Abstracts and the database of Forest Laboratories Inc. were searched in February 2005

DARE.2007

44. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil

Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil Weycker D, Taneja C, Edelsberg J, Erder M H, Schmitt F A, Setyawan J, Oster G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to assess the cost-effectiveness of adjuvant memantine in patients with moderate-to-severe Alzheimer’s disease, who were receiving stable doses of donepezil. The authors concluded that memantine plus donepezil improved the clinical outcomes and reduced the total costs of care

NHS Economic Evaluation Database.2007

45. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from

NIHR HTA programme2006

46. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technology Assessment 2006; 10(1): 1-176 Authors' objectives The objective of this review was to provide an update review of the best quality evidence for the clinical effectiveness and cost

Health Technology Assessment (HTA) Database.2006

47. Cost-effectiveness of memantine in community-based Alzheimer's disease patients: an adaptation in Spain

Cost-effectiveness of memantine in community-based Alzheimer's disease patients: an adaptation in Spain Cost-effectiveness of memantine in community-based Alzheimer's disease patients: an adaptation in Spain Cost-effectiveness of memantine in community-based Alzheimer's disease patients: an adaptation in Spain Antonanzas F, Rive B, Badenas J M, Gomez-Lus S, Guilhaume C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study assessed the use of memantine in patients with Alzheimer's disease (AD). This treatment was compared with standard care, which the authors defined as no pharmacological treatment. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population

NHS Economic Evaluation Database.2006

48. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease

Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease. London: National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance 111. 2006 Authors' objectives This guidance constitutes a review of 'NICE technology appraisal guidance 19' on the use of donepezil, galantamine and rivastigmine for the treatment of mild to moderately

Health Technology Assessment (HTA) Database.2006

49. Memantine plus donepezil improves physical and mental health in people with Alzheimer’s disease

Memantine plus donepezil improves physical and mental health in people with Alzheimer’s disease Memantine plus donepezil improves physical and mental health in people with Alzheimer’s disease | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword (...) Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Memantine plus donepezil improves physical and mental health in people with Alzheimer’s disease Article Text Therapeutics Memantine plus donepezil improves physical and mental health in people with Alzheimer’s disease Free Rupert H McShane , MD, MRCPsych Statistics from Altmetric.com No Altmetric data

Evidence-Based Mental Health2005

50. Memantine for treatment of moderate to severe Alzheimer's disease

Memantine for treatment of moderate to severe Alzheimer's disease Memantine for treatment of moderate to severe Alzheimer's disease Memantine for treatment of moderate to severe Alzheimer's disease Canadian Coordinating Office for Health Technology Assessment Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Coordinating Office (...) for Health Technology Assessment. Memantine for treatment of moderate to severe Alzheimer's disease. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2005: 4 Authors' objectives The aim of this report is to summarize the use of memantine (trademarked Ebixa, distributed by Lundbeck Canada Inc.)for the treatment of moderate to severe Alzheimer's disease. Authors' conclusions Health Canada has issued a Notice of Compliance with conditions for memantine in the treatment

Health Technology Assessment (HTA) Database.2005

52. Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective

Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective Jones R W, McCrone P, Guilhaume C Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health intervention studied was memantine (20mg/day), a moderate-affinity uncompetitive NMDA antagonist approved in the EU for the treatment of moderately severe-to-severe Alzheimer's disease. Type of intervention Treatment. Economic study type Cost-effectiveness

NHS Economic Evaluation Database.2004

53. Memantine

Memantine Memantine Memantine Sangha K Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Sangha K. Memantine. University HealthSystem Consortium (UHC). Drug Monograph. 2004 Authors' objectives The UHC Drug Monographs are a continuing series of authoritative, concise evaluations of new and emerging pharmaceuticals. Monographs are written by drug information (...) literature and provides recommendations for appropriate use. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Memantine /therapeutic use Language Published English Country of organisation United States Address for correspondence University HealthSystem Consortium, 2001 Spring Rd., Suite 700, Oak Brook, IL 60523 USA. Tel: 630-954-1700; Fax: 630-954-4730; Email: travis@uhc.edu AccessionNumber 32006001056 Date bibliographic record published 13/09/2006 Date abstract record published 13

Health Technology Assessment (HTA) Database.2004

55. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. 14734594 2004 01 21 2004 01 29 2016 12 08 1538-3598 291 3 2004 Jan 21 JAMA JAMA Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. 317-24 Memantine is a low- to moderate-affinity, uncompetitive N-methyl-D-aspartate receptor antagonist. Controlled trials have demonstrated the safety (...) and efficacy of memantine monotherapy for patients with moderate to severe Alzheimer disease (AD) but no controlled trials of memantine in patients receiving a cholinesterase inhibitor have been performed. To compare the efficacy and safety of memantine vs placebo in patients with moderate to severe AD already receiving stable treatment with donepezil. A randomized, double-blind, placebo-controlled clinical trial of 404 patients with moderate to severe AD and Mini-Mental State Examination scores of 5 to 14

JAMA2004

56. Namenda (Memantine HCI)

Namenda (Memantine HCI) Drug Approval Package: Namenda (Memantine HCI) NDA #021487 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Namenda (Memantine HCI) Tablets Company: Forest Laboratories Inc. Application No.: 021487 Approval Date: 10/16/2003 (PDF) (PDF) Medical Review(s) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Pharmacology Review(s) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Bioequivalence Review(s) (PDF) (PDF) (PDF) Administrative Document(s) (PDF

FDA - Drug Approval Package2003

57. Memantine in moderate-to-severe Alzheimer's disease.

Memantine in moderate-to-severe Alzheimer's disease. 12672860 2003 04 03 2003 04 09 2013 11 21 1533-4406 348 14 2003 Apr 03 The New England journal of medicine N. Engl. J. Med. Memantine in moderate-to-severe Alzheimer's disease. 1333-41 Overstimulation of the N-methyl-D-aspartate (NMDA) receptor by glutamate is implicated in neurodegenerative disorders. Accordingly, we investigated memantine, an NMDA antagonist, for the treatment of Alzheimer's disease. Patients with moderate-to-severe (...) Alzheimer's disease were randomly assigned to receive placebo or 20 mg of memantine daily for 28 weeks. The primary efficacy variables were the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) and the Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory modified for severe dementia (ADCS-ADLsev). The secondary efficacy end points included the Severe Impairment Battery and other measures of cognition, function, and behavior. Treatment differences

NEJM2003

58. Memantine for Alzheimer's disease and vascular dementia - horizon scanning review

Memantine for Alzheimer's disease and vascular dementia - horizon scanning review Memantine for Alzheimer's disease and vascular dementia - horizon scanning review Memantine for Alzheimer's disease and vascular dementia - horizon scanning review NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Memantine for Alzheimer's disease (...) and vascular dementia - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). New and Emerging Technology Briefing. 2001 Authors' objectives To summarise the current research evidence on memantine for Alzheimer's disease and vascular dementia. Authors' conclusions - Clinical impact: Memantine is the first treatment being developed for patients suffering from moderate to severe Alzheimer's disease and for patients suffering from vascular dementia. This is a growing patient group

Health Technology Assessment (HTA) Database.2001